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Depression in Pregnancy 
Background 
1. Definition  
o Depression occurring in pregnant pt  
2. General info  
o Maternal mental illness can have adverse effect on infant development  
 Cognitive 
 Social 
 Emotional 
 Behavioral 
o Preconception counseling of depressed pts ideal 
o Early detection and Tx of depression in pregnancy critical  
 Depression can adversely affect birth outcomes and neonatal health 
o Incr risk of recurrent depression if antidepressant discontinued during 
pregnancy 
o High likelihood of postpartum depression if left untreated 
 
Pathophysiology  
1. Pathology of dz  
o Disturbance in neurological pathways  
 Primarily norepinephrine, serotonin, and dopamine 
2. Incidence/prevalence  
o 14-23% of pregnant women
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3. Risk factors  
o Hx of  
 Mood disorders 
 Anxiety disorders 
 Postpartum depression 
 Ante partum depression 
o FHx of mental illness, esp during pregnancy or postpartum 
o Psychosocial  
 Hx of abuse  
 Emotional, child, sexual, domestic 
 Lack of social support 
 Unplanned pregnancy 
 Substance abuse 
 Younger age 
 Ambivalence about pregnancy 
 Single 
 Higher parity 
 Adverse life events 
 Marital instability 
4. Morbidity/mortality  
o Maternal  
 Impaired judgment 
 Insomnia 
 Poor prenatal care 
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 Incr substance use 
 Preterm delivery 
 Incr incidence of post partum depression 
 Anxiety 
 Psychosis 
 Suicide ideation and suicide 
 Development of chronic mood disorders 
 Effects on attachment and bonding 
o Fetal  
 Possible incr risk of preterm delivery
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 Incr risk irritability 
 Less activity and attentiveness 
 Fewer facial expressions 
 Inconclusive data on  
 Miscarriage risk 
 Low birth wt 
 SGA at delivery 
 Possible genetic predisposition to depression 
 
Diagnostics  
1. History  
o Same as nonpregnant pt (see DSM-IV-R)  
 Many Sx of depression overlap w/Sx of pregnancy
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 See Depression (Adult)  
o Determine severity of depression  
 Suicidal thoughts or self harm  
 Psychotic thoughts  
 Functional incapacitation  
 Wt loss  
o Characteristics of previous depressive episodes  
 Severity  
 Recurrences  
 Suicide attempts  
 Medication efficacy  
2. Physical exam  
o See Depression (Adult)  
3. Diagnostic testing  
o Laboratory evaluation  
 Consider TSH, Hct, urine toxicology screen  
4. Edinburgh Postnatal Depression Scale   
o Found effective as screening tool in pregnancy  
o If suicidal thoughts  
 Consider hospital admission or urgent psychiatric referral  
5. Diagnostic criteria  
o See DSM-IV-R  
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Differential Diagnoses 
1. Bipolar disorder/bipolar spectrum disorders 
2. Hypothyroidism 
3. Anemia 
4. See Depression (Adult) 
5. See Postpartum depression 
 
Therapeutics 
1. Acute Tx  
o Mild to moderate  
 Cognitive behavioral therapy (CBT) and interpersonal therapy (IPT) 
shown to be effective
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o Moderate to severe  
 Psychotherapy + pharmacologic therapy 
 Psychosocial interventions 
o Severe w/suicidal or psychotic features  
 Hospitalization w/urgent psychiatric evaluation 
2. Pharmacologic therapy  
o General  
 Selective serotonin reuptake inhibitors (SSRIs) mainstay 
 All antidepressants cross placenta and can enter breast milk 
 Selection should be based on hx of efficacy, teratogenicity, plans to 
breastfeed (see Postpartum depression)
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 Single medication at higher dose preferred over multiple drugs
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o SSRIs  
 General  
 Discontinuation of SSRI during pregnancy may incr risk of 
recurrent depression
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 Incr risk for preterm birth in mothers w/depression and/or 
taking SSRIs in pregnancy
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 All cross placenta and found in breast milk 
 Avoid starting paroxetine Category D 
 SSRI exposure late in pregnancy may be associated w/  
 Poor neonatal adaptation (PNA) 
 Self-limited symptoms such as tachypnea, hypoglycemia, 
temperature instability, irritability, weak cry, and seizures
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 Persistent pulmonary hypertension (PPHN)
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 Tricyclic antidepressants (TCAs)  
 Neonatal effects 
 Little data on safety 
 SNRIs  
 Very little data on safety 
 Buproprion  
 Very little data 
3. Electroconvulsive therapy (ECT)  
o Requires psychiatric consultation 
o Consider for acute psychosis or suicide ideation w/intent
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4. Informed consent  
o Discussion of risks and benefits or medication +/- other Tx options 
documented in chart 
o Involves in-depth individual risk-benefit analysis 
o Discussion to include parents, primary care provider, obstetric provider, 
neonatology, and psychiatrist when indicated 
5. Long-term care  
o See pts weekly until depressive symptoms stabilize  
 Drug dose may need to be incr late second trimester due to decr 
serum concentrations during pregnancy 
o Reassess for suicidality each visit 
o Sx indicate need for psychiatric referral  
 Psychotic thoughts 
 Active suicidal thoughts 
 Comorbid substance use 
 Complicated polypharmacy 
 Resistant depression 
o Admit to hospital  
 Psychotic features 
 Suicidality 
 Unable to care for self or other children 
 
Prognosis 
1. Likelihood of recurrence in future pregnancies predicted by  
o Severity of depression 
o Response to Tx 
o Total number of lifetime depressive episodes 
2. Depressed prenatal pts are at high risk for postpartum depression 
3. Pts should be monitored closely for up to a yr following delivery 
 
Prevention 
1. Preconception counseling 
2. Address psychosocial risk factors prior to pregnancy 
3. Women on medication w/mild or no depressive Sx for 6 mo or longer and no hx of 
recurrent depression  
o May consider tapering off and discontinuing meds prior to conception 
4. In women w/prior prenatal depression, make sure pt is euthymic before attempting 
conception 
5. Contraceptive counseling and close follow-up to prevent/discourage unplanned, 
closely spaced pregnancies 
 
Patient Information 
1. Handout from U.S. Department of Health and Human Services: 
http://www.womenshealth.gov/FAQ/depression-pregnancy.cfm#top 
2. Handout from Health Resources and Services Administration (HRSA): 
http://www.mchb.hrsa.gov/pregnancyandbeyond/depression/default.htm 
3. Handout from American Congress of Obstetricians and Gynecologists (ACOG): 
http://www.acog.org/publications/patient_education/bp106.cfm 
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